CR20110524A - Proceso para preparar compuestos antivirales - Google Patents

Proceso para preparar compuestos antivirales

Info

Publication number
CR20110524A
CR20110524A CR20110524A CR20110524A CR20110524A CR 20110524 A CR20110524 A CR 20110524A CR 20110524 A CR20110524 A CR 20110524A CR 20110524 A CR20110524 A CR 20110524A CR 20110524 A CR20110524 A CR 20110524A
Authority
CR
Costa Rica
Prior art keywords
antiviral compounds
salts
compound
prepare antiviral
prepare
Prior art date
Application number
CR20110524A
Other languages
English (en)
Inventor
James J Napier
Jean-Christophe Califano
Su Yu
Calvin L Becker
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR20110524A publication Critical patent/CR20110524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(a) Procesos para preparar un compuesto y sales del mismo que, entre otros, son de utilidad para inhibir al virus de la hepatitis C (HCV); (b) intermediarios de utilidad para la preparación del compuesto y las sales; (c) composiciones farmacéuticas que comprenden al compuesto o las sales; y (d) métodos para usar de dichas composiciones.
CR20110524A 2009-03-24 2011-10-04 Proceso para preparar compuestos antivirales CR20110524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16270509P 2009-03-24 2009-03-24
US31671310P 2010-03-23 2010-03-23

Publications (1)

Publication Number Publication Date
CR20110524A true CR20110524A (es) 2012-01-19

Family

ID=42136100

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110524A CR20110524A (es) 2009-03-24 2011-10-04 Proceso para preparar compuestos antivirales

Country Status (24)

Country Link
EP (1) EP2411372B1 (es)
JP (1) JP5744003B2 (es)
KR (1) KR101665955B1 (es)
CN (1) CN102361858B (es)
AU (1) AU2010229975B2 (es)
BR (1) BRPI1009854A2 (es)
CA (1) CA2753825C (es)
CL (1) CL2011002278A1 (es)
CO (1) CO6450678A2 (es)
CR (1) CR20110524A (es)
DO (1) DOP2011000297A (es)
EC (1) ECSP11011415A (es)
ES (1) ES2488821T3 (es)
GT (1) GT201100241A (es)
HK (1) HK1166798A1 (es)
IL (1) IL214858A (es)
MX (1) MX2011010049A (es)
MY (1) MY169288A (es)
NZ (1) NZ594923A (es)
PE (1) PE20120519A1 (es)
RU (1) RU2524573C2 (es)
SG (1) SG174211A1 (es)
WO (1) WO2010111348A1 (es)
ZA (1) ZA201106511B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
KR101774742B1 (ko) 2010-07-16 2017-09-11 애브비 아일랜드 언리미티드 컴퍼니 촉매 반응용 포스핀 리간드
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
JP5819959B2 (ja) 2010-07-16 2015-11-24 アッヴィ・バハマズ・リミテッド 抗ウイルス性化合物を調製するための方法
WO2012129099A1 (en) * 2011-03-18 2012-09-27 Abbott Laboratories Formulations of phenyl uracil compounds
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021624A1 (fr) * 1999-09-20 2001-03-29 Fuji Photo Film Co., Ltd. Composes destines au marquage par fluorescence
CZ2002992A3 (cs) * 1999-09-22 2002-06-12 Aventis Pharma Deutschland Gmbh Konjugáty 4-benzylaminochinolinů se ľlučovými kyselinami a jejich heteroanalogy, způsob jejich přípravy, farmaceutické prostředky je obsahující, a jejich pouľití
DE10051981A1 (de) * 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
EP2038253A1 (en) * 2006-05-30 2009-03-25 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
EP2377854A1 (en) * 2007-09-17 2011-10-19 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors
KR101552474B1 (ko) * 2007-09-17 2015-09-11 애브비 바하마스 리미티드 Ｃ형 간염 치료용 우라실 또는 티민 유도체
KR20110033291A (ko) * 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물

Also Published As

Publication number Publication date
GT201100241A (es) 2015-08-19
JP2012521990A (ja) 2012-09-20
KR20110137372A (ko) 2011-12-22
CN102361858A (zh) 2012-02-22
JP5744003B2 (ja) 2015-07-01
CA2753825A1 (en) 2010-09-30
ES2488821T3 (es) 2014-08-29
WO2010111348A1 (en) 2010-09-30
IL214858A (en) 2015-05-31
CL2011002278A1 (es) 2012-03-09
RU2524573C2 (ru) 2014-07-27
HK1166798A1 (en) 2012-11-09
PE20120519A1 (es) 2012-06-03
KR101665955B1 (ko) 2016-10-13
CO6450678A2 (es) 2012-05-31
NZ594923A (en) 2013-11-29
DOP2011000297A (es) 2011-10-15
IL214858A0 (en) 2011-11-30
BRPI1009854A2 (pt) 2015-08-25
CA2753825C (en) 2017-10-17
AU2010229975A1 (en) 2011-09-29
ECSP11011415A (es) 2011-11-30
MY169288A (en) 2019-03-21
EP2411372A1 (en) 2012-02-01
EP2411372B1 (en) 2014-07-23
RU2011142757A (ru) 2013-04-27
MX2011010049A (es) 2011-10-11
CN102361858B (zh) 2014-07-23
SG174211A1 (en) 2011-10-28
ZA201106511B (en) 2012-05-30
AU2010229975B2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
ECSP13012438A (es) Proceso para preparar compuestos antivirales
UY33897A (es) Inhibidores del virus de la hepatitis c
CR20170316A (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
DOP2010000084A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
UY34066A (es) Inhibidores del virus de la hepatitis c
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
CL2014000612A1 (es) Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CU20130157A7 (es) 4 - aril- n- fenil- 1,3,5- triazin- 2- aminas que contienen un grupo sulfoximina
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
ECSP14013189A (es) Inhibidores de la replicación de los virus de la gripe
CO6561783A2 (es) Inhibidores del virus flaviviridae
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
CR20110524A (es) Proceso para preparar compuestos antivirales
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
CL2012002362A1 (es) Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c.
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
BR112014013972A8 (pt) inibidores de hcv nssa
CO6321288A2 (es) Sales de compuestos inhibidores de vih
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX360161B (es) Proceso para preparar compuestos antiviricos.